NEWS
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
Inhibikase Therapeutics (Nasdaq: IKT) announced the completion of enrollment in its Phase 2 '201' trial of risvodetinib (risvo), a selective c-Abl inhibitor, for untreated Parkinson's disease patients. The 12-week, randomized, double-blind, placebo-controlled trial involves 120 participants across 32 U.S. sites, with the company expecting to report results in Q4 2024. Out of the enrolled participants, 69 have completed the dosing period. To date, 32 mild and 5 moderate adverse events possibly related to the treatment have been reported, with four participants withdrawing early from the study.
Positive
Completion of enrollment in the Phase 2 '201' trial for risvodetinib.
Trial results expected in Q4 2024.
120 participants enrolled across 32 U.S. sites.
69 participants have completed the 12-week dosing period.
Advancement towards discussions with the FDA for pivotal Phase 3 trials.
Negative
32 mild and 5 moderate adverse events observed possibly related to risvodetinib treatment.
Four participants withdrew from the trial before completing the 12-week treatment.
Positive
Completion of enrollment in the Phase 2 '201' trial for risvodetinib.
Trial results expected in Q4 2024.
120 participants enrolled across 32 U.S. sites.
69 participants have completed the 12-week dosing period.
Advancement towards discussions with the FDA for pivotal Phase 3 trials.
Negative
32 mild and 5 moderate adverse events observed possibly related to risvodetinib treatment.
Four participants withdrew from the trial before completing the 12-week treatment.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1075Followers
68Following
7407Visitors
Follow